The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use. As ...

The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

Respiratory Drugs Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with ...

Please provide your email address to receive an email when new articles are posted on . Among new initiators of multiple-inhaler triple therapy for asthma, discontinuation was high, although ...

Current drug treatments have been incorporated into clinical practice guidelines, such as the NAEPP EPR-3 for asthma [101] and GOLD treatment guidelines for COPD, [102] both of which recognize the ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...